Home/Filings/4/0001641172-25-002299
4//SEC Filing

Brown Regina 4

Accession 0001641172-25-002299

CIK 0001335105other

Filed

Apr 1, 8:00 PM ET

Accepted

Apr 2, 10:36 AM ET

Size

15.3 KB

Accession

0001641172-25-002299

Insider Transaction Report

Form 4
Period: 2025-03-31
Brown Regina
Director
Transactions
  • Award

    Options to Purchase Common Stock

    2025-03-31+9,5089,508 total
    Exercise: $1.21From: 2025-03-31Exp: 2030-03-31Common (9,508 underlying)
Holdings
  • Options to Purchase Common Stock

    Exercise: $5.88From: 2023-06-30Exp: 2028-06-30Common (10,000 underlying)
    10,000
  • Options to Purchase Common Stock

    Exercise: $30.30From: 2021-06-30Exp: 2026-06-30Common (10,000 underlying)
    10,000
  • Options to Purchase Common Stock

    Exercise: $1.30From: 2024-09-30Exp: 2029-09-30Common (6,269 underlying)
    6,269
  • Options to Purchase Common Stock

    Exercise: $2.37From: 2024-06-30Exp: 2029-06-30Common (10,000 underlying)
    10,000
  • Options to Purchase Common Stock

    Exercise: $2.33From: 2025-01-20Exp: 2030-01-20Common (4,924 underlying)
    4,924
  • Options to Purchase Common Stock

    Exercise: $2.37From: 2024-06-30Exp: 2029-06-30Common (4,904 underlying)
    4,904
  • Options to Purchase Common Stock

    Exercise: $7.45From: 2022-06-30Exp: 2027-06-30Common (10,000 underlying)
    10,000
  • Options to Purchase Common Stock

    Exercise: $28.00From: 2021-05-11Exp: 2026-05-11Common (25,000 underlying)
    25,000
Footnotes (1)
  • [F1]Effective March 31, 2025, the reporting person was granted stock options to purchase an aggregate of 9,508 shares vesting immediately. The grant was in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.

Documents

1 file

Issuer

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

CIK 0001335105

Entity typeother

Related Parties

1
  • filerCIK 0001862089

Filing Metadata

Form type
4
Filed
Apr 1, 8:00 PM ET
Accepted
Apr 2, 10:36 AM ET
Size
15.3 KB